Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.
Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.
Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the presentation of clinical data for KVD900 at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. KVD900 demonstrates rapid plasma kallikrein inhibition and significantly improves symptoms of hereditary angioedema (HAE) attacks within 24 hours. The Phase 2 trial involved 68 patients, with 53 successfully completing it. KVD900 has received FDA Fast Track designation and EMA approval for its Pediatric Investigational Plan, indicating promising regulatory support for its development.
KalVista Pharmaceuticals (NASDAQ:KALV) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET. A live webcast is available at www.kalvista.com, with an audio archive accessible for 30 days post-event.
KalVista focuses on small molecule protease inhibitors for unmet medical needs, particularly targeting hereditary angioedema and diabetic macular edema. Their candidate KVD900, aimed at acute HAE attacks, completed a significant Phase 2 trial in February 2021.
KalVista Pharmaceuticals (NASDAQ: KALV) announces KVD900's acceptance for oral presentation at the 12th C1-Inhibitor Deficiency & Angioedema Workshop from June 3-6, 2021. The presentation will detail a Phase 2 trial's findings, showcasing KVD900's pharmacokinetic and pharmacodynamic profile and its effectiveness in treating hereditary angioedema (HAE) attacks. This highlights KalVista's ongoing commitment to addressing unmet needs in HAE treatment through innovative therapies.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Dr. Paul K. Audhya as Chief Medical Officer. Dr. Audhya brings over 20 years of experience in clinical development and global medical affairs across various therapeutic areas. This strategic addition aims to enhance the company's late-stage drug development and global commercialization efforts, particularly as they advance their oral hereditary angioedema franchise. Dr. Audhya expressed enthusiasm about joining KalVista at a pivotal time for their innovative therapies.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the FDA has placed a clinical hold on its Phase 2 trial for KVD824, an oral candidate for hereditary angioedema (HAE). The FDA requested further information and refinements to the study protocol without demanding new studies. CEO Andrew Crockett expressed intent to comply with FDA requests, noting that this hold does not affect the development of KVD900, which is preparing for a Phase 3 trial. Historical data show safe dosing of KVD824 in prior studies, with no serious adverse events reported.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Nancy Stuart to its Board of Directors, effective March 18, 2021. Stuart, currently COO at Concert Pharmaceuticals, brings over 25 years of experience in the biopharmaceutical industry. CEO Andrew Crockett highlighted her strategic and operational expertise as valuable for the company's transition to a commercial-stage organization focusing on oral treatments for hereditary angioedema (HAE). KalVista is advancing clinical-stage assets, including KVD900, an oral therapy for acute HAE attacks, which recently showed positive Phase 2 trial results.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) provided a Q3 fiscal update ending January 31, 2021, highlighting significant progress in treating hereditary angioedema (HAE) with KVD900 and KVD824. KVD900 showed strong Phase 2 results, significantly outperforming placebo on multiple endpoints. The company closed a public offering, raising approximately $222.5 million. However, revenue fell to $0 from $1.6 million due to the expiration of the Merck Option Agreement. Net loss increased to $10.1 million, while cash reserves decreased to $50.3 million, attributed to R&D spending.
KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. A live webcast will be available on the company's website, along with an audio archive for 30 days post-event.
KalVista focuses on developing small molecule protease inhibitors, including KVD900 for acute hereditary angioedema (HAE) attacks and KVD824 for prophylactic HAE treatment, with significant clinical trial advancements in early 2021.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has successfully closed its upsized public offering, selling 6,181,250 shares at $36.00 each, raising approximately $222.5 million in gross proceeds. This includes the underwriters' option for an additional 806,250 shares. Jefferies LLC, Stifel, Nicolaus & Company, and Cantor Fitzgerald acted as joint book-running managers. The offering is registered with the SEC and follows prior effective registration statements. KalVista specializes in developing small molecule protease inhibitors for critical diseases, including hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has priced its upsized public offering of 5,375,000 shares of common stock at $36.00 per share, projecting gross proceeds of $193.5 million. The offering will close around February 16, 2021, pending customary conditions. An additional 806,250 shares may be purchased by underwriters. Funds will support the Phase 3 trial of KVD900, Phase 2 trial of KVD824, and development of oral Factor XIIa programs. Jefferies, Stifel, and Cantor Fitzgerald are managing the offering.
